NEW YORK, March 9, 2018 /PRNewswire/ --
According to Hexa Research, the U.S. medical cannabis market size was valued at USD $5.44
Billion in 2016 and is expected to hit USD $19.48 billion by 2024. The industry is expected
to witness swift growth during the forecast period due to the numerous medical benefits of cannabis products and the accelerating
pace of legalization of such products in the United States. The report also indicated that the
increasing demand for medical cannabis is due to the increasing ageing population. In 2016, rising number of patients diagnosed
with chronic pain has resulted in increasing use of cannabis. The report estimated that the demand for medical cannabis for
arthritis will grow at a CAGR of 17.8% over the projected period as it forecasted more adults and children will have arthritis.
Cannabis infused edibles is also expected to grow at a CAGR of 17.8% over the forecast period. Pivot Pharmaceuticals
Inc. (OTC: PVOTF), GW Pharmaceuticals plc (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Cara Therapeutics,
Inc. (NASDAQ: CARA), General Cannabis Corp. (OTC: CANN).
California's new recreational cannabis laws went into effect on January 1st, 2018. While California is the largest market, Canada is projected to show strong sales as well. Deloitte's report estimates the Canadian market will be
worth at least $5B in sales in 2018. Tom Adams, Editor-in-Chief at
Arcview Market Research and Principal Analyst at BDS Analytics explained, "Our data shows positive indicators across the board
for the legal cannabis industry, in North America and around the globe. The passage of the 2016
ballot initiatives and continued maturation of the existing Adult-Use markets are the primary drivers of the growth this year.
That's nothing compared to what we can expect in 2018 and beyond from Nevada's tourism, and
California and Canada planning to launch Adult-Use sales in
2018."
Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) also listed on the Canadian Stock Exchange under the Ticker
'PVOT'. Earlier this week the company announced, "The acquisition of Thrudermic, LLC ("TDL" or "Thrudermic"), a privately
held North Carolina company. Pivot previously announced a licensing agreement with Thrudermic
but has decided to exercise its option to acquire 100% of TDL. Pivot will pay $1.00 (USD) for all
of the issued and outstanding units of Thrudermic, and issue an aggregate of 500,000 common shares in the capital of Pivot to Dr.
Joseph Borovsky and Dr. Leonid Lurya for their intellectual
property portfolio, including patents, good will and know-how in connection with the TDL Transdermal Nanotechnology. Dr.
Borovsky, has been appointed Pivot's Vice President, Product Formulation, and Dr. Lurya has been appointed Executive Director,
Product Formulation."
The TDL Transdermal Nanotechnology is intended for the formulation and delivery of dosable bio-cannabis products. On behalf of
Pivot, Thrudermic recently filed three additional patent applications related to improved formulation and delivery for new routes
of administration of cannabinoids and will increase the number of products in the Company's pipeline.
"Thrudermic is very excited to become part of the Pivot organization. Our lipid-based nano-dispersion technology is well
suited for the emerging cannabis industry. Pivot's goal is to increase cannabinoid bioavailability, drug release rates and
improve product stability, and consumers should be able to confidently take correct and accurate doses to help meet their health
and wellness needs," states Dr. Borovsky.
Dr. Borovsky, formerly the director of research and development for Mead Corporation, received his Bachelor of Science degree
in Chemistry from UCLA and his Ph.D. in Physical Organic Chemistry from the University of Massachusetts at Amherst. He also completed a year of post-doctoral research in Medicinal Chemistry
at Washington State University College of Pharmacy and was a Research Fellow in Synthetic Organic
Chemistry at Harvard University. Dr. Lurya is the inventor of Thrudermic transdermal technology and
has authored several patents. He received his MD from the Moscow Medical Institute No. 2, Russia, and then completed his PhD in Biophysics, Chemical Physics Department at the Weizmann Institute of
Science, Israel."
Dr. Patrick Frankham, Pivot's CEO, comments, "Thrudermic is Pivot's fourth disruptive
formulation and delivery platform for cannabinoids. We are thrilled that Dr. Borovsky and Dr. Lurya have agreed to join us to
develop and commercialize therapeutic bio-cannabis products. They are highly experienced formulations experts with many years of
pharmaceutical industry know-how. Pivot continues to position itself as a leader in the delivery of dosable bio-cannabis,
something that consumers and regulatory agencies will demand as legalization occurs."
GW Pharmaceuticals plc (NASDAQ: GWPH) is a biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along
with its U.S. subsidiary Greenwich Biosciences, is advancing an orphan drug program in the field of childhood-onset epilepsy with
a focus on Epidiolex (cannabidiol), for which GW has submitted regulatory applications in the U.S. On February 27, 2018, the company announced the European Medicines Agency (EMA) has granted orphan drug
designation for cannabidiol (CBD) for the treatment of tuberous sclerosis (TS). GW is currently recruiting a Phase 3 clinical
trial of Epidiolex® (cannabidiol) as an adjunctive therapy for the treatment of seizures associated with TS, with data expected
in the second half of 2018. Subject to positive results, GW expects to submit regulatory applications in 2019 for Epidiolex in TS
in both the U.S. and Europe.
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) is a clinical-stage specialty pharmaceutical company dedicated to
developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare
neuropsychiatric diseases with high unmet medical needs. Recently, the company announced the results of a positive meeting held
with the U.S. Food and Drug Administration (FDA) regarding its planned development strategy for ZYN002 in Fragile X syndrome
(FXS). FXS is a rare genetic developmental disability that is the leading known cause of both inherited intellectual disability
and autism spectrum disorder. ZYN002 is the first and only pharmaceutically-produced cannabidiol (CBD) formulated as a
patent-protected permeation-enhanced transdermal gel. Zynerba has received U.S. Orphan Drug designation for the use of CBD as a
treatment of FXS. Currently, there are no approved therapies to treat FXS or its most common symptoms. Based on the company's
dialogue with the FDA, the Company expects to initiate a single pivotal study mid-year 2018 to support a New Drug Application
(NDA) for ZYN002 in FXS. The FDA and the Company are in agreement that the primary and key secondary endpoints for the study
should assess observable behaviors in patients with FXS as reported by the caregiver using the validated Aberrant Behavior
Checklist in Fragile X syndrome (ABC-FXS).
Cara Therapeutics, Inc. (NASDAQ: CARA) is a clinical-stage biopharmaceutical company focused on developing and
commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid
receptors (KORs). Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS
cannabinoid receptors. Cara's most advanced CB compound, CR701, is in preclinical development. Dr. Joseph
Stauffer, CMO Cara Therapeutics, said, "Cannabinoid Receptor Agonists like CR701 have the potential to provide improved
pain relief for patients suffering from neuropathic pain."
General Cannabis Corp. (OTCQB: CANN) is the comprehensive national resource for the highest-quality service providers
available to the regulated cannabis industry. On February 2, 2018, the company announced that its
client, Green Leaf Medical LLC, a leading grower and supplier of medical cannabis in Maryland,
has successfully harvested its first crop and has passed all state-required laboratory tests. Now producing an estimated 500-600
pounds of high-quality medical marijuana on a monthly basis, Green Leaf is one of the leading fully approved suppliers in
Maryland. Green Leaf also announced that it has begun the next phase of its expansion,
increasing the size of its facility to approximately 50,000 square feet, a 67 percent increase from current capacity. The
expanded grow house should be completed before the end of the year, raising production totals to nearly 1,000 pounds per
month.
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination,
branding, marketing and advertising for third parties for corporate news and original content through our unique media platform
that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial
Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials
for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the
information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting
high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com
does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along
with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our
unique financial newswire and media platform. For pivot pharmaceuticals inc. financial news dissemination and PR services,
FinancialBuzz.com has been compensated five thousand dollars by vintage capital group inc. Our fees
may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a
combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance
is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or
cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the
editorial or Site or continue to post information about any companies the information contained herein is not intended to be used
as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information
contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are
not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles,
quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full
responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own
investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any
pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the
content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular
security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided
by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is
suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult
with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to
the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information
is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer,
disclosure and Terms of Use, please visit: http://www.financialbuzz.com.
Media Contact:
info@financialbuzz.com
+1-877-601-1879
URL: http://www.FinancialBuzz.com
SOURCE FinancialBuzz.com